First Line Therapy

 

FDA Approves Centocor's Remicade As First-Line Rheumatoid Arthritis Therapy
----------------------------------------------------------------------------
----

WASHINGTON (Reuters Health) Jan 02 - The US Food And Drug Administration(FDA) has approved Centocor Inc.'s Remicade (infliximab) for combination use with methotrexate as a first-line therapy to inhibit the progression of structural damage in patients with moderate-to-severe rheumatoid arthritis, the company said on Tuesday.

The agent was approved in October 1999 as a second-line treatment for rheumatoid arthritis in patients who have had an inadequate response to methotrexate alone, which is the standard therapy for treating the disease.

Clinical studies of Remicade have demonstrated that the drug slows
rheumatoid arthritis-related joint damage by inhibiting its two contributing causes; joint erosion and the narrowing of the joint space between the bones

In a study that followed 428 patients with rheumatoid arthritis, 52%
receiving Remicade and methotrexate reported a decrease in signs and symptoms of the disease, including pain, stiffness and swollen joints, compared with 17% of patients given methotrexate alone, the company said in a news release.

Centocor, a wholly owned subsidiary of Johnson & Johnson, estimates that the cost of treating rheumatoid arthritis with Remicade runs between $10,000 and $12,000 per patient, compared with $1,000 for methotrexate alone.

Side effects of Remicade, which was initially approved by the FDA in 1998 for the short-term treatment of Crohn's disease, include upper respiratory infection, headache, mild infusion-related reactions, sinusitis, rash and cough.

The drug's labeling stresses that the physicians should use caution in prescribing the drug in patients with a chronic infection or with a history of recurrent infection.

Potentially fatal infections including sepsis and disseminated tuberculosis have been reported in patients using Remicade, particularly in those on concomitant immunosuppressive drugs, the product's label warns.

Separately, 28 people throughout North America and Europe have developed tuberculosis--and one patient died--after they were given Remicade, the European Agency for the Evaluation of Medicinal Products (EMEA) reported.

In a public statement dated December 20, the EMEA said: "To date, 28 cases of TB have been reported (nine cases in North America and 19 cases in Europe) of which one had a fatal outcome.... "

"In a significant proportion, the onset of active TB occurred after three or less infusions of Remicade, thus supporting a possible relationship with initiation of Remicade therapy," the agency added.

The EMEA said that in view of the seriousness of these reports, it was recommending that Remicade treatment should be stopped if active TB was suspected in any patient until the diagnosis was ruled out or the infection had been treated.

Around 100,000 patients worldwide have taken Remicade since it was launched in the United States in August 1998 and since it received European marketing authorization in August 1999.

The drug is marketed by Schering-Plough in Europe and by Johnson & Johnson in the United States.

Despite the approval, shares in Centocor dipped 2-7/16, or slightly more than 4%, to 54-5/16 in late-afternoon trading on the New York Stock Exchange.

Up ] Next ]

DISCLAIMER:

The materials and information on this server are intended for educational and informational purposes only. The materials and information are not intended to replace the services of a trained health professional or to be a substitute for medical advice of physicians and/or other health care professionals. The International Still's Disease Foundation is not engaged in rendering medical or professional medical services. You should consult your physician on specific medical questions, particularly in matters requiring diagnosis or medical attention. The International Still's Disease Foundation makes no representations or warranties with respect to any treatment, action, application medication or preparation by any person following the information offered or provided within this website.  Any information used from other websites was done so with permission from each site, with an exception to those of "public domain", whereas we believe any site without a cited reference was a "public domain site" and for our use.  The International Still's Disease Foundation is a non-profit organization.   This page was last updated on January 17, 2001

Copyrightę 1999-2001 International Still's Disease Foundation